Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

A legfontosabb adatok

Ki végzi
Neurocrine Biosciences
Hol
Aurora, Cleveland, Durham, Miami, Orange, Rochester és Washington D.C. (Egyesült Államok)Mind a 7 helyszín megnézéseMég 4 másik országban, 5 helyszínen
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
19 fő vett részt
Kezdés
2022. jún. 7.
Befejezés
2025. jan. 27.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • NBI-827104
A regiszteradat frissítve
2026. február 13.
Miért állt le
Business decision

Ki vehet részt

Életkor
4 év – 12 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:
  • Completed 12 weeks of treatment in Study NBI-827104-CSWS2010; For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:
  • Have diagnosis of EECSWS confirmed by the Diagnosis Confirmation Panel (DCP)

Ki nem vehet részt

  • Presence of relevant neurological disorders other than EECSWS and its underlying conditions as judged by the investigator. Symptomatic conditions underlying EECSWS (for example, neonatal strokes) have to be stable for at least 1 year prior to screening
  • Planned surgical intervention related to structural abnormalities of the brain from screening through the Week 6 Visit
  • Used any active investigational drug other than NBI-827104 in the context of a clinical study within 30 days or 5 half-lives (whichever is longer) before screening or plans to use such an investigational drug (other than NBI-827104) during the study
  • Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance; For Participants Who Do Not Enroll Directly from or Did Not Participate in Study NBI-827104-CSWS2010:
  • Have developed any other disorder for which the treatment takes priority over treatment of EECSWS or is likely to interfere with study treatment or impair treatment compliance
  • Clinically relevant findings related to cardiovascular or laboratory parameters at screening as determined by the investigator
  • For participants who enroll directly following the completion of the Study NBI-827104-CSWS2010:
  • Body weight <15 kg at Day 1

Helyszínek itt: Egyesült Államok

Még 4 másik országban, 5 helyszínen

  • Aurora, ColoradoHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Durham, North CarolinaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Orange, CaliforniaHospital not named in the registry
  • Rochester, New YorkHospital not named in the registry
  • Washington D.C., District of ColumbiaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).

A vizsgálat csoportja

  • NBI-827104A vizsgált kezelés

    NBI-827104 administered orally

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
A regiszteradat frissítve
2026. február 13.